Wainua News

AstraZeneca's nerve drug Wainua failed a late-stage heart disease trial, causing investor concern and a slide in the company's share price. The company's future

AstraZeneca's stock market value has slumped by over £20 billion after its Wainua drug failed to meet a key goal to reduce deaths related to heart disease. The

AstraZeneca's shares declined after its Ionis-partnered drug, Wainua, failed to meet its primary endpoints in a late-stage heart disease trial, not reducing car